Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H. Endocr Relat Cancer. 2019 Feb 1;26(2):227-239. doi: 10.1530/ERC-18-0424.

 

The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy. Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Fimmers R, Essler M, Ahmadzadehfar H. Clin Cancer Res. 2018 Oct 1;24(19):4672-4679. doi: 10.1158/1078-0432.CCR-18-0947.

 

Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma. Alexander N, Vali R, Ahmadzadehfar H, Shammas A, Baruchel S. Curr Radiopharm. 2018;11(1):14-21. doi: 10.2174/1874471011666171215093112. Review.

 

Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.Marinova M, Mücke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, Conrad R, Ahmadzadehfar H. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):38-46. doi: 10.1007/s00259-017-3816-z.

 

Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour. Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214. doi: 10.1007/s00259-017-3652-1.

 

A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours. Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, Schmidt-Wolf I, Lingohr P, Fischer S, Kristiansen G, Essler M. Horm Metab Res. 2017 Feb;49(2):77-85. doi: 10.1055/s-0042-121894. Review.

 

Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis. Yordanova A, Mayer K, Essler M, Ahmadzadehfar. Clin Nucl Med. 2016 Dec;41(12):977-979.

 

Befundabfrage

Mo. - Fr.: 08:00 Uhr - 16:00 Uhr

Tel.: +49 (0)228 / 287 - 11089

Fax: +49 (0) 228 / 287-16615

anmeldungnuklearmedizin@ukbonn.de

Terminvergabe


Bitte vereinbaren Sie telefonisch einen Termin.

Schilddrüsenambulanz:
Tel.: +49 (0) 228 / 287-16171

Fax: +49 (0) 228 / 287-19179

PET/CT:
Tel.: +49 (0) 228 / 287 - 11088
Fax: +49 (0) 228 / 287-16207

Konventionelle Szintigraphie:
Tel.: +49 (0) 228 / 287-16171

Therapie-Sekretariat:
Tel.: +49 (0) 228 / 287-16974

Fax: +49 (0) 228 / 287-19057

Therapiestation Winkler:
Tel.: +49 (0) 228 / 287-16855
Fax: +49 (0) 228 / 287-19107

 

Oberarztsekretariat: S. Döbeling

Tel.: 0228 / 287 - 16181

Fax: 0228 / 287 - 19057

 

Die Anmeldung erfolgt im Haus 21 (Nuklearmedizin)

 

Klinik und Poliklinik für Nuklearmedizin

Universitätsklinikum Bonn (AöR)

Sigmund-Freud-Straße 25

D-53127 Bonn